Vulvar and vaginal squamous cell carcinoma · line 1 · Cisplatin radiosensitization (concurrent with EBRT + brachytherapy)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

Línea de tratamiento	1
Track	estándar
Régimen vinculado	`REG-CISPLATIN-RADIOSENS`

ID	`IND-VULVAR-VAGINAL-SCC-LA-1L-CISPLATIN-RT`
Tipo	Indicación
Situación	reviewed 2026-07-11 \| pending_clinical_signoff
Enfermedades	`DIS-VULVAR-VAGINAL-SCC`
Fuentes	`SRC-NCCN-CERVICAL-2025`

Notas

STUB pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted per CHARTER §8.3 — draft content only, NOT published/verified clinical advice). PARTIAL — RT dose/field not modellable per KNOWLEDGE_SCHEMA_SPECIFICATION §17, mirrors the IND-CERVICAL-LOCALLY- ADVANCED-CRT pattern exactly. REG-CISPLATIN-RADIOSENS is reused UNCHANGED (no existing file was modified) — its own notes/notes_ua describe cervical FIGO IB3-IVA dosing context, but the weekly- cisplatin component dose (40 mg/m², cap 70mg) is the identical radiosensitizing backbone applied here; RT field/dose for vulvar/vaginal SCC (primary + groin ± pelvic nodes) is planned by radiation oncology, distinct from the cervical pelvic RT + brachytherapy field. No vulvar/vaginal-specific pivotal chemoradiation RCT was found — evidence is extrapolated from cervical (GOG-120) and anal (ACT II) chemoradiation paradigms; flagged as an open evidentiary gap rather than asserting invented response-rate numbers for this specific disease.

Utilizado por

Algoritmos

ALGO-VULVAR-VAGINAL-SCC-1L - ALGO-VULVAR-VAGINAL-SCC-1L

Enfermedad

DIS-VULVAR-VAGINAL-SCC - Carcinoma de células escamosas vaginales y vulvares

Indicación

IND-VULVAR-VAGINAL-SCC-1L-WLE-SLNB - IND-VULVAR-VAGINAL-SCC-1L-WLE-SLNB